A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
Sendhilnathan RamalingamSharareh Siamakpour-ReihaniLauren BohannanYi RenAlexander SibleyJeff ShengLi MaAndrew B NixonJing LyuDaniel C ParkerJames BainMichael MuehlbauerOlga IlkayevaVirginia Byers KrausJanet L HuebnerThomas SpitzerJami BrownJonathan U PeledMarcel van den BrinkAntonio GomesTaewoong ChoiCristina GasparettoMitchell HorwitzGwynn LongRichard LopezDavid RizzieriStefanie SarantopoulosNelson ChaoAnthony D SungPublished in: PloS one (2021)
Pasireotide did not prevent gastrointestinal toxicity or acute GVHD compared to contemporaneous controls. Pasireotide was associated with numerically higher chronic GVHD and significantly decreased OS and RFS compared to contemporaneous controls. Pasireotide may provide a locally protective effect in the stool microbiome and in local inflammation as measured by stool calprotectin, stool beta-defensin, and stool diversity index.
Keyphrases
- hematopoietic stem cell
- liver failure
- oxidative stress
- allogeneic hematopoietic stem cell transplantation
- respiratory failure
- drug induced
- stem cell transplantation
- bone marrow
- hepatitis b virus
- acute myeloid leukemia
- intensive care unit
- disease activity
- rheumatoid arthritis
- oxide nanoparticles
- mechanical ventilation
- acute respiratory distress syndrome